Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts

被引：46

作者：

Wallach, Joshua D. ^{[1
]}

Ross, Joseph S. ^{[2
]}

机构：

[1] Yale Law Sch, Collaborat Res Integr & Transparency, New Haven, CT USA

[2] Yale Univ, Sch Med, Dept Internal Med, POB 208093, New Haven, CT 06520 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2018年 / 319卷 / 08期

基金：

美国医疗保健研究与质量局; 美国国家卫生研究院;

关键词：

TRIAL;

D O I：

10.1001/jama.2017.21897

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：776 / 778

页数：3

共 14 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2] Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012 [J].

Downing, Nicholas S. ;

Aminawung, Jenerius A. ;

Shah, Nilay D. ;

Krumholz, Harlan M. ;

Ross, Joseph S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (04) :368-377

[3] Association of Off-label Drug Use and Adverse Drug Events in an Adult Population [J].

Eguale, Tewodros ;

Buckeridge, David L. ;

Verma, Aman ;

Winslade, Nancy E. ;

Benedetti, Andrea ;

Hanley, James A. ;

Tamblyn, Robyn .

JAMA INTERNAL MEDICINE, 2016, 176 (01) :55-63

[4]

goodrx, GOODRX TOP 10

[5]

Hamer Ann M, 2002, J Manag Care Pharm, V8, P266

[6] Gabapentinoid Use in the United States 2002 Through 2015 [J].

Johansen, Michael E. .

JAMA INTERNAL MEDICINE, 2018, 178 (02) :292-294

[7]

Krumholz SD, 2011, ARCH INTERN MED, V171, P1100, DOI 10.1001/archinternmed.2011.241

[8] The Neurontin legacy - Marketing through Misinformation and Manipulation [J].

Landefeld, C. Seth ;

Steinman, Michael A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :103-106

[9] Gabapentin for Chronic Neuropathic Pain [J].

Moore, Andrew ;

Derry, Sheena ;

Wiffen, Philip .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (08) :818-819

[10] Off label use: a mistake or a need? [J].

REVISTA DE SAUDE PUBLICA, 2012, 46 (02) :398-399

← 1 2 →